A multicenter study of recombinant factor VIII (Recombinate): safety, efficacy, and inhibitor risk in previously untreated patients with hemophilia A. The Recombinate Study Group - Bray,G.L.; Gomperts,E.D.; Courter,S. (Blood, 1994)